Cogent Biosciences, Inc. announced fourth quarter and full year 2025 financial results, reporting cash and cash equivalents of $900.8 million as of December 31, 2025, sufficient to fund operations into 2028, alongside key milestones including SUMMIT NDA submission for bezuclastinib in NonAdvSM and topline data from APEX and PEAK trials.
Key takeaways
SUMMIT NDA for bezuclastinib in NonAdvSM submitted December 2025; acceptance expected February 2026
PEAK NDA initiated for bezuclastinib in 2L GIST under RTOR; completion on track for April 2026
APEX topline: 57% objective response rate per mIWG, 80% per PPR in AdvSM
PEAK Phase 3 topline: 16.5 months mPFS vs 9.2 months (HR=0.50) in 2L GIST
Cash, cash equivalents and marketable securities: $900.8 million as of December 31, 2025
Q4 2025 net loss $102.5 million; full year $328.9 million